APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiation Toxicity Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Radiation Toxicity Therapeutics Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchRadiation Toxicity Therapeutics Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiation Toxicity Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Radiation Toxicity Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiation Toxicity Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiation Toxicity Therapeutics Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Radiation Toxicity Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Radiation Toxicity Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Radiation Toxicity Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Radiation Toxicity Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Radiation Toxicity Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Radiation Toxicity Therapeutics include Coherus BioSciences, Jubilant Life Sciences, Mission Pharmacal Company, Partner Therapeutics, Recipharm AB, Siegfried Holdings, Viatris, Amgen and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Radiation Toxicity Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Radiation Toxicity Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Radiation Toxicity Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Radiation Toxicity Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Radiation Toxicity Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Radiation Toxicity Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Radiation Toxicity Therapeutics Segment by Company

Coherus BioSciences

Jubilant Life Sciences

Mission Pharmacal Company

Partner Therapeutics

Recipharm AB

Siegfried Holdings

Viatris

Amgen

Novartis

Radiation Toxicity Therapeutics Segment by Type

Ionizing Radiation

Non-ionizing Radiation

Radiation Toxicity Therapeutics Segment by Application

Hospital

Research & Academic Institutes

Radiation Toxicity Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiation Toxicity Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiation Toxicity Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiation Toxicity Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Radiation Toxicity Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Radiation Toxicity Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radiation Toxicity Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Radiation Toxicity Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ionizing Radiation Major Player Table 3. Non-ionizing Radiation Major Player Table 4. Global Radiation Toxicity Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Research & Academic Institutes Major Player Table 7. Radiation Toxicity Therapeutics Industry Trends Table 8. Radiation Toxicity Therapeutics Industry Drivers Table 9. Radiation Toxicity Therapeutics Industry Opportunities and Challenges Table 10. Radiation Toxicity Therapeutics Industry Restraints Table 11. Global Radiation Toxicity Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Radiation Toxicity Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Radiation Toxicity Therapeutics Market Share by Region (2021-2026) Table 14. Global Radiation Toxicity Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Radiation Toxicity Therapeutics Market Share by Region (2027-2032) Table 16. Global Radiation Toxicity Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Radiation Toxicity Therapeutics Revenue Market Share by Players (2021-2026) Table 18. Global Radiation Toxicity Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Radiation Toxicity Therapeutics Key Players Headquarters & Area Served Table 20. Global Radiation Toxicity Therapeutics Players, Product Type & Application Table 21. Global Radiation Toxicity Therapeutics Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Radiation Toxicity Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Radiation Toxicity Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Radiation Toxicity Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Radiation Toxicity Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Radiation Toxicity Therapeutics Revenue Market Share by Type (2021-2026) Table 28. Global Radiation Toxicity Therapeutics Revenue Market Share by Type (2027-2032) Table 29. Global Radiation Toxicity Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Radiation Toxicity Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Radiation Toxicity Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Radiation Toxicity Therapeutics Revenue Market Share by Application (2021-2026) Table 33. Global Radiation Toxicity Therapeutics Revenue Market Share by Application (2027-2032) Table 34. Coherus BioSciences Company Information Table 35. Coherus BioSciences Business Overview Table 36. Coherus BioSciences Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Coherus BioSciences Radiation Toxicity Therapeutics Product Portfolio Table 38. Coherus BioSciences Recent Development Table 39. Jubilant Life Sciences Company Information Table 40. Jubilant Life Sciences Business Overview Table 41. Jubilant Life Sciences Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Jubilant Life Sciences Radiation Toxicity Therapeutics Product Portfolio Table 43. Jubilant Life Sciences Recent Development Table 44. Mission Pharmacal Company Company Information Table 45. Mission Pharmacal Company Business Overview Table 46. Mission Pharmacal Company Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Mission Pharmacal Company Radiation Toxicity Therapeutics Product Portfolio Table 48. Mission Pharmacal Company Recent Development Table 49. Partner Therapeutics Company Information Table 50. Partner Therapeutics Business Overview Table 51. Partner Therapeutics Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Partner Therapeutics Radiation Toxicity Therapeutics Product Portfolio Table 53. Partner Therapeutics Recent Development Table 54. Recipharm AB Company Information Table 55. Recipharm AB Business Overview Table 56. Recipharm AB Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Recipharm AB Radiation Toxicity Therapeutics Product Portfolio Table 58. Recipharm AB Recent Development Table 59. Siegfried Holdings Company Information Table 60. Siegfried Holdings Business Overview Table 61. Siegfried Holdings Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Siegfried Holdings Radiation Toxicity Therapeutics Product Portfolio Table 63. Siegfried Holdings Recent Development Table 64. Viatris Company Information Table 65. Viatris Business Overview Table 66. Viatris Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Viatris Radiation Toxicity Therapeutics Product Portfolio Table 68. Viatris Recent Development Table 69. Amgen Company Information Table 70. Amgen Business Overview Table 71. Amgen Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Amgen Radiation Toxicity Therapeutics Product Portfolio Table 73. Amgen Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Radiation Toxicity Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Novartis Radiation Toxicity Therapeutics Product Portfolio Table 78. Novartis Recent Development Table 79. North America Radiation Toxicity Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 80. North America Radiation Toxicity Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 81. North America Radiation Toxicity Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 82. North America Radiation Toxicity Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 83. North America Radiation Toxicity Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. North America Radiation Toxicity Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 85. North America Radiation Toxicity Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 86. Europe Radiation Toxicity Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 87. Europe Radiation Toxicity Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 88. Europe Radiation Toxicity Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 89. Europe Radiation Toxicity Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 90. Europe Radiation Toxicity Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. Europe Radiation Toxicity Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 92. Europe Radiation Toxicity Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 93. China Radiation Toxicity Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 94. China Radiation Toxicity Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 95. China Radiation Toxicity Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 96. China Radiation Toxicity Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 97. Asia Radiation Toxicity Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 98. Asia Radiation Toxicity Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 99. Asia Radiation Toxicity Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 100. Asia Radiation Toxicity Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia Radiation Toxicity Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 102. Asia Radiation Toxicity Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 103. Asia Radiation Toxicity Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 104. SAMEA Radiation Toxicity Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 105. SAMEA Radiation Toxicity Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 106. SAMEA Radiation Toxicity Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 107. SAMEA Radiation Toxicity Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 108. SAMEA Radiation Toxicity Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. SAMEA Radiation Toxicity Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 110. SAMEA Radiation Toxicity Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Radiation Toxicity Therapeutics Image Figure 2. Global Radiation Toxicity Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiation Toxicity Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ionizing Radiation Image Figure 5. Non-ionizing Radiation Image Figure 6. Global Radiation Toxicity Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Radiation Toxicity Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Research & Academic Institutes Image Figure 10. Global Radiation Toxicity Therapeutics Market Size (US$ Million) & (2021-2032) Figure 11. Global Radiation Toxicity Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Radiation Toxicity Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Radiation Toxicity Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Radiation Toxicity Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Radiation Toxicity Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Radiation Toxicity Therapeutics Revenue Market Share by Type (2021-2032) Figure 18. Global Radiation Toxicity Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Radiation Toxicity Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Radiation Toxicity Therapeutics Revenue Market Share by Application (2021-2032) Figure 21. North America Radiation Toxicity Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032) Figure 23. North America Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032) Figure 24. North America Radiation Toxicity Therapeutics Revenue Share by Country (2021-2032) Figure 25. United States Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Radiation Toxicity Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032) Figure 30. Europe Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032) Figure 31. Europe Radiation Toxicity Therapeutics Revenue Share by Country (2021-2032) Figure 32. Germany Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Radiation Toxicity Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032) Figure 42. China Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032) Figure 43. Asia Radiation Toxicity Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032) Figure 45. Asia Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Radiation Toxicity Therapeutics Revenue Share by Region (2021-2032) Figure 47. Japan Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Radiation Toxicity Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032) Figure 55. SAMEA Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032) Figure 56. SAMEA Radiation Toxicity Therapeutics Revenue Share by Country (2021-2032) Figure 57. Brazil Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Radiation Toxicity Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Ionizing Radiation
  • Non-ionizing Radiation
Applications
  • Hospital
  • Research & Academic Institutes
Companies covered
  • Coherus BioSciences
  • Jubilant Life Sciences
  • Mission Pharmacal Company
  • Partner Therapeutics
  • Recipharm AB
  • Siegfried Holdings
  • Viatris
  • Amgen
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Radiation Toxicity Therapeutics Market by Type
  3. 1.2.1 Global Radiation Toxicity Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ionizing Radiation
  5. 1.2.3 Non-ionizing Radiation
  6. 1.3 Radiation Toxicity Therapeutics Market by Application
  7. 1.3.1 Global Radiation Toxicity Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Research & Academic Institutes
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Radiation Toxicity Therapeutics Market Dynamics
  1. 2.1 Radiation Toxicity Therapeutics Industry Trends
  2. 2.2 Radiation Toxicity Therapeutics Industry Drivers
  3. 2.3 Radiation Toxicity Therapeutics Industry Opportunities and Challenges
  4. 2.4 Radiation Toxicity Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Radiation Toxicity Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Radiation Toxicity Therapeutics Growth Trends by Region
  3. 3.2.1 Global Radiation Toxicity Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Radiation Toxicity Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Radiation Toxicity Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Radiation Toxicity Therapeutics Revenue by Players
  2. 4.1.1 Global Radiation Toxicity Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Radiation Toxicity Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Radiation Toxicity Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Radiation Toxicity Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Radiation Toxicity Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Radiation Toxicity Therapeutics Players, Product Type & Application
  8. 4.5 Global Radiation Toxicity Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Radiation Toxicity Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Radiation Toxicity Therapeutics Tier 1, Tier 2, and Tier 3
5 Radiation Toxicity Therapeutics Market Size by Type
  1. 5.1 Global Radiation Toxicity Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Radiation Toxicity Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Radiation Toxicity Therapeutics Revenue Market Share by Type (2021-2032)
6 Radiation Toxicity Therapeutics Market Size by Application
  1. 6.1 Global Radiation Toxicity Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Radiation Toxicity Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Radiation Toxicity Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Coherus BioSciences
  2. 7.1.1 Coherus BioSciences Company Information
  3. 7.1.2 Coherus BioSciences Business Overview
  4. 7.1.3 Coherus BioSciences Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Coherus BioSciences Radiation Toxicity Therapeutics Product Portfolio
  6. 7.1.5 Coherus BioSciences Recent Developments
  7. 7.2 Jubilant Life Sciences
  8. 7.2.1 Jubilant Life Sciences Company Information
  9. 7.2.2 Jubilant Life Sciences Business Overview
  10. 7.2.3 Jubilant Life Sciences Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Jubilant Life Sciences Radiation Toxicity Therapeutics Product Portfolio
  12. 7.2.5 Jubilant Life Sciences Recent Developments
  13. 7.3 Mission Pharmacal Company
  14. 7.3.1 Mission Pharmacal Company Company Information
  15. 7.3.2 Mission Pharmacal Company Business Overview
  16. 7.3.3 Mission Pharmacal Company Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mission Pharmacal Company Radiation Toxicity Therapeutics Product Portfolio
  18. 7.3.5 Mission Pharmacal Company Recent Developments
  19. 7.4 Partner Therapeutics
  20. 7.4.1 Partner Therapeutics Company Information
  21. 7.4.2 Partner Therapeutics Business Overview
  22. 7.4.3 Partner Therapeutics Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Partner Therapeutics Radiation Toxicity Therapeutics Product Portfolio
  24. 7.4.5 Partner Therapeutics Recent Developments
  25. 7.5 Recipharm AB
  26. 7.5.1 Recipharm AB Company Information
  27. 7.5.2 Recipharm AB Business Overview
  28. 7.5.3 Recipharm AB Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Recipharm AB Radiation Toxicity Therapeutics Product Portfolio
  30. 7.5.5 Recipharm AB Recent Developments
  31. 7.6 Siegfried Holdings
  32. 7.6.1 Siegfried Holdings Company Information
  33. 7.6.2 Siegfried Holdings Business Overview
  34. 7.6.3 Siegfried Holdings Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Siegfried Holdings Radiation Toxicity Therapeutics Product Portfolio
  36. 7.6.5 Siegfried Holdings Recent Developments
  37. 7.7 Viatris
  38. 7.7.1 Viatris Company Information
  39. 7.7.2 Viatris Business Overview
  40. 7.7.3 Viatris Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Viatris Radiation Toxicity Therapeutics Product Portfolio
  42. 7.7.5 Viatris Recent Developments
  43. 7.8 Amgen
  44. 7.8.1 Amgen Company Information
  45. 7.8.2 Amgen Business Overview
  46. 7.8.3 Amgen Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Amgen Radiation Toxicity Therapeutics Product Portfolio
  48. 7.8.5 Amgen Recent Developments
  49. 7.9 Novartis
  50. 7.9.1 Novartis Company Information
  51. 7.9.2 Novartis Business Overview
  52. 7.9.3 Novartis Radiation Toxicity Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Novartis Radiation Toxicity Therapeutics Product Portfolio
  54. 7.9.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Radiation Toxicity Therapeutics Revenue (2021-2032)
  2. 8.2 North America Radiation Toxicity Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Radiation Toxicity Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Radiation Toxicity Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Radiation Toxicity Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Radiation Toxicity Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Radiation Toxicity Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Radiation Toxicity Therapeutics Revenue by Country
  11. 8.6.1 North America Radiation Toxicity Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Radiation Toxicity Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Radiation Toxicity Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Radiation Toxicity Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Radiation Toxicity Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Radiation Toxicity Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Radiation Toxicity Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Radiation Toxicity Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Radiation Toxicity Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Radiation Toxicity Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Radiation Toxicity Therapeutics Revenue by Country
  11. 9.6.1 Europe Radiation Toxicity Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Radiation Toxicity Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Radiation Toxicity Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Radiation Toxicity Therapeutics Revenue (2021-2032)
  2. 10.2 China Radiation Toxicity Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Radiation Toxicity Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Radiation Toxicity Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Radiation Toxicity Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Radiation Toxicity Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Radiation Toxicity Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Radiation Toxicity Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Radiation Toxicity Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Radiation Toxicity Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Radiation Toxicity Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Radiation Toxicity Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Radiation Toxicity Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Radiation Toxicity Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Radiation Toxicity Therapeutics Revenue by Country
  11. 11.6.1 Asia Radiation Toxicity Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Radiation Toxicity Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Radiation Toxicity Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Radiation Toxicity Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Radiation Toxicity Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Radiation Toxicity Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Radiation Toxicity Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Radiation Toxicity Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Radiation Toxicity Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Radiation Toxicity Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Radiation Toxicity Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Radiation Toxicity Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Radiation Toxicity Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Radiation Toxicity Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Radiation Toxicity Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Radiation Toxicity Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst